{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:49:06Z","timestamp":1794923346487,"version":"4.9.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Linear IgA bullous dermatosis (LABD), also known as linear IgA disease, is a subepidermal blistering disorder presenting with linear deposits of IgA along the basement membrane zone. Although LABD is commonly idiopathic, it can also rarely be triggered by certain drugs, including vancomycin. Herein, we document the rare case of a 41-year-old woman with a history of invasive ductal breast carcinoma, receiving an anticancer regimen of pembrolizumab, cyclophosphamide, and doxorubicin, who developed erythema, tense bullae, and extensive sloughing of skin after vancomycin therapy. Initially, the patient was suspected to have drug-induced Stevens\u2013Johnson syndrome\/toxic epidermal necrosis; however, biopsies of the right thigh revealed subepidermal bullous dermatosis with neutrophils and necrotic keratinocytes. Direct immunofluorescence revealed 3+\/3+ anti-IgA and 1+\/3+ anti-C3 deposits that were linear at the dermal\u2013epidermal junction. The clinical and histopathologic findings confirmed the diagnosis of vancomycin-induced LABD. This report examines the complicated relationship between immunobullous disease, neoplasms, and oncologic treatment. Presented is a rare case of vancomycin-induced LABD in a patient receiving concurrent chemotherapy and immunotherapy. Clinician awareness of the increased susceptibility of vancomycin-induced LABD in this population subset can improve clinical outcomes and decrease morbidity\/mortality.<\/jats:p>","DOI":"10.1097\/dad.0000000000003023","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:00:10Z","timestamp":1750921210000},"page":"798-802","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Vancomycin-Induced Linear IgA Bullous Dermatosis Mimicking Stevens\u2013Johnson Syndrome Associated With Anticancer Therapy"],"prefix":"10.1097","volume":"47","author":[{"given":"Maedot A.","family":"Haymete","sequence":"first","affiliation":[{"name":"Virginia Tech Carilion School of Medicine, Roanoke, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Casado","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine, Roanoke, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa T.","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla C.","family":"Guerra","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine, Roanoke, VA;"},{"name":"Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary E.","family":"Holcomb","sequence":"additional","affiliation":[{"name":"Virginia Tech Carilion School of Medicine, Roanoke, VA;"},{"name":"Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6346-094X","authenticated-orcid":false,"given":"Douglas J.","family":"Grider","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA;"},{"name":"Dominion Pathology Associates, Roanoke, VA; and"},{"name":"Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"R1-20250919","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0190-9622(94)70015-X","article-title":"Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature","volume":"30","author":"Kuechle","year":"1994","journal-title":"J Am Acad Dermatol."},{"key":"R2-20250919","first-page":"7318305","article-title":"A rare case of vancomycin-induced linear immunoglobulin a bullous dermatosis","volume":"2017","author":"Jha","year":"2017","journal-title":"Case Rep Dermatol Med."},{"key":"R4-20250919","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0738-081X(00)00185-1","article-title":"Linear IgA bullous dermatosis","volume":"19","author":"Guide","year":"2001","journal-title":"Clin Dermatol."},{"key":"R5-20250919","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2230.1989.tb01980.x","article-title":"HLA type in bullous pemphigoid, cicatricial pemphigoid and linear IgA disease","volume":"14","author":"Venning","year":"1989","journal-title":"Clin Exp Dermatol."},{"key":"R6-20250919","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2340\/00015555-3154","article-title":"Drug-induced linear IgA bullous dermatosis: a case report and review of the literature","volume":"99","author":"Lammer","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"R7-20250919","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/biomedicines11020323","article-title":"A review of bullous dermatologic adverse events associated with anti-cancer therapy","volume":"11","author":"Parisi","year":"2023","journal-title":"Biomedicines"},{"key":"R8-20250919","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol."},{"key":"R9-20250919","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3947\/ic.2016.48.4.267","article-title":"Treatment of methicillin-resistant staphylococcus aureus bacteremia","volume":"48","author":"Choo","year":"2016","journal-title":"Infect Chemother."},{"issue":"suppl 1","key":"R10-20250919","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis."},{"issue":"suppl 1","key":"R11-20250919","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis."},{"key":"R13-20250919","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.anai.2016.03.030","article-title":"Immune-mediated reactions to vancomycin: a systematic case review and analysis","volume":"116","author":"Minhas","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"R14-20250919","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ced.13030","article-title":"Piperacillin\u2013tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis overlap","volume":"42","author":"Adler","year":"2017","journal-title":"Clin Exp Dermatol."},{"key":"R15-20250919","first-page":"157","article-title":"Early diagnosis is key in vancomycin-induced linear IgA bullous dermatosis and Stevens-Johnson syndrome","volume":"104","author":"Jones","year":"2004","journal-title":"J Am Osteopathic Assoc."},{"key":"R16-20250919","first-page":"e30309","article-title":"Linear immunoglobulin A (IgA) bullous dermatosis mimicking Stevens-Johnson syndrome","volume":"14","author":"Park","year":"2022","journal-title":"Cureus"},{"key":"R17-20250919","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/DAD.0000000000002352","article-title":"Drug-induced linear IgA bullous dermatosis mimicking Stevens\u2013Johnson syndrome treated with etanercept: a case report","volume":"45","author":"Kwinta","year":"2023","journal-title":"Am J Dermatopathol."},{"key":"R18-20250919","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"R19-20250919","first-page":"1","article-title":"Generalized peeling skin syndrome: case report and review of the literature","volume":"16","author":"Kharfi","year":"2010","journal-title":"Dermatol Online J."},{"key":"R20-20250919","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cup.13576","article-title":"Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: a case report with literature review","volume":"47","author":"Colmant","year":"2020","journal-title":"J Cutan Pathol."},{"key":"R21-20250919","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/ijd.17041","article-title":"Adult-onset linear IgA bullous dermatosis: a retrospective single-center cohort study of 81 patients and literature review","volume":"63","author":"Wang","year":"2024","journal-title":"Int J Dermatol."},{"key":"R22-20250919","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13023-019-1089-2","article-title":"Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients","volume":"14","author":"Genovese","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"R23-20250919","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/ijd.15627","article-title":"Linear IgA\/IgG bullous dermatosis after nivolumab therapy","volume":"60","author":"Perandones-Gonz\u00e1lez","year":"2021","journal-title":"Int J Dermatol."},{"key":"R24-20250919","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1345\/aph.10268","article-title":"Linear immunoglobulin a bullous dermatosis induced by gemcitabine","volume":"35","author":"del Pozo","year":"2001","journal-title":"Ann Pharmacother."},{"key":"R25-20250919","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/bjd.21653","article-title":"Atezolizumab-induced linear IgA bullous dermatosis","volume":"187","author":"Aguilar-Duran","year":"2022","journal-title":"Br J Dermatol."},{"key":"R26-20250919","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"R27-20250919","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-9966-31-50","article-title":"Chemotherapy and skin reactions","volume":"31","author":"Fabbrocini","year":"2012","journal-title":"J Exp Clin Cancer Res."},{"key":"R28-20250919","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/skinhd\/vzae008","article-title":"Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation","volume":"5","author":"Saeed","year":"2025","journal-title":"Skin Health Dis."},{"key":"R29-20250919","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"R30-20250919","doi-asserted-by":"crossref","first-page":"e01671","DOI":"10.1016\/j.idcr.2022.e01671","article-title":"Vancomycin-induced linear IgA bullous dermatosis in a patient with cancer","volume":"31","author":"Itoh","year":"2023","journal-title":"IDCases"},{"key":"R31-20250919","first-page":"60","article-title":"Vancomycin-related linear IgA bullous dermatosis in a patient with cervical cancer","volume":"37","author":"Lee","year":"2005","journal-title":"Infect Chemother."},{"key":"R32-20250919","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archdermatol.2009.68","article-title":"Localized palmar vancomycin-induced linear IgA bullous dermatosis occurring at supratherapeutic levels","volume":"145","author":"Walsh","year":"2009","journal-title":"Arch Dermatol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:00:24Z","timestamp":1758294024000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003023","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}